Top

Published in:

01-09-2012 | Preclinical Study

Cucurbitacin E inhibits breast tumor metastasis by suppressing cell migration and invasion

Authors: Tao Zhang, Jingjie Li, Yanmin Dong, Dong Zhai, Li Lai, Fujun Dai, Huayun Deng, Yihua Chen, Mingyao Liu, Zhengfang Yi

Published in: Breast Cancer Research and Treatment | Issue 2/2012

Abstract

Tumor metastasis is the main cause of cancer-related deaths of patients. Breast cancer is highly malignant with considerable metastatic potential, which urges the necessity for developing novel potential drug candidate to prevent tumor metastasis. Here, we report our finding with Cucurbitacin E (CuE, α-elaterin), a tetracyclic triterpenes compound isolated from Cucurbitaceae. The potency of CuE on breast cancer metastasis inhibition was assessed in vivo and in vitro. In our animal experiments, intraperitoneal administrations of CuE significantly inhibited breast tumor metastasis to the lung without affecting apoptosis or proliferation of inoculated 4T1 and MDA-MB-231 breast cancer cells. Treatment of metastatic breast tumor cells with CuE markedly blocked tumor cell migration and invasion in vitro. Subsequent studies showed that CuE impaired Arp2/3-dependent actin polymerization and suppressed Src/FAK/Rac1/MMP involved pathway. Overall, our data demonstrate that CuE blocks breast cancer metastasis by suppressing tumor cell migration and invasion. We provide first evidence of a novel role for CuE as a potential candidate for treating breast cancer metastasis.

Available only for authorised users

Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61(4):212–236. doi:10.3322/caac.20121 PubMedCrossRef

Weigelt B, Peterse JL, van’t Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5(8):591–602. doi:10.1038/nrc1670 PubMedCrossRef

Nguyen DX, Bos PD, Massague J (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9(4):274–284. doi:10.1038/nrc2622 PubMedCrossRef

Steeg PS (2006) Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12(8):895–904. doi:10.1038/nm1469 PubMedCrossRef

Ideses Y, Brill-Karniely Y, Haviv L, Ben-Shaul A, Bernheim-Groswasser A (2008) Arp2/3 branched actin network mediates filopodia-like bundles formation in vitro. PLoS ONE 3(9):e3297. doi:10.1371/journal.pone.0003297 PubMedCrossRef

Li Z, Kim ES, Bearer EL (2002) Arp2/3 complex is required for actin polymerization during platelet shape change. Blood 99(12):4466–4474PubMedCrossRef

Yamakita Y, Oosawa F, Yamashiro S, Matsumura F (2003) Caldesmon inhibits Arp2/3-mediated actin nucleation. J Biol Chem 278(20):17937–17944. doi:10.1074/jbc.M208739200M208739200 PubMedCrossRef

Gabarra-Niecko V, Schaller MD, Dunty JM (2003) FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev 22(4):359–374PubMedCrossRef

Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141(1):52–67. doi:10.1016/j.cell.2010.03.015 PubMedCrossRef

10.

Kunnumakkara AB, Anand P, Aggarwal BB (2008) Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 269(2):199–225. doi:10.1016/j.canlet.2008.03.009 PubMedCrossRef

11.

Mitra SK, Hanson DA, Schlaepfer DD (2005) Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 6(1):56–68. doi:10.1038/nrm1549 PubMedCrossRef

12.

Siesser PM, Hanks SK (2006) The signaling and biological implications of FAK overexpression in cancer. Clin Cancer Res 12(11 Pt 1):3233–3237. doi:10.1158/1078-0432.CCR-06-0456 PubMedCrossRef

13.

Chambliss OL, Jones CM (1966) Cucurbitacins: specific insect attractants in Cucurbitaceae. Science 153(3742):1392–1393. doi:10.1126/science.153.3742.1392 PubMedCrossRef

14.

Kocyan A, Zhang LB, Schaefer H, Renner SS (2007) A multi-locus chloroplast phylogeny for the Cucurbitaceae and its implications for character evolution and classification. Mol Phylogenet Evol 44(2):553–577. doi:10.1016/j.ympev.2006.12.022 PubMedCrossRef

15.

Duncan KL, Duncan MD, Alley MC, Sausville EA (1996) Cucurbitacin E-induced disruption of the actin and vimentin cytoskeleton in prostate carcinoma cells. Biochem Pharmacol 52(10):1553–1560PubMedCrossRef

16.

Momma K, Masuzawa Y, Nakai N, Chujo M, Murakami A, Kioka N, Kiyama Y, Akita T, Nagao M (2008) Direct interaction of Cucurbitacin E isolated from Alsomitra macrocarpa to actin filament. Cytotechnology 56(1):33–39. doi:10.1007/s10616-007-9100-5 PubMedCrossRef

17.

Greige-Gerges H, Abou Khalil R, Chahine R, Haddad C, Harb W, Ouaini N (2007) Effect of cucurbitacins on bilirubin-albumin binding in human plasma. Life Sci 80(6):579–585. doi:10.1016/j.lfs.2006.10.005 PubMedCrossRef

18.

Musza LL, Speight P, McElhiney S, Barrow CJ, Gillum AM, Cooper R, Killar LM (1994) Cucurbitacins, cell adhesion inhibitors from Conobea scoparioides. J Nat Prod 57(11):1498–1502PubMedCrossRef

19.

Dong Y, Lu B, Zhang X, Zhang J, Lai L, Li D, Wu Y, Song Y, Luo J, Pang X, Yi Z, Liu M (2010) Cucurbitacin E, a tetracyclic triterpenes compound from Chinese medicine, inhibits tumor angiogenesis through VEGFR2-mediated Jak2-STAT3 signaling pathway. Carcinogenesis 31(12):2097–2104. doi:10.1093/carcin/bgq167 PubMedCrossRef

20.

Shan D, Chen L, Njardarson JT, Gaul C, Ma X, Danishefsky SJ, Huang XY (2005) Synthetic analogues of migrastatin that inhibit mammary tumor metastasis in mice. Proc Natl Acad Sci USA 102(10):3772–3776. doi:10.1073/pnas.0500658102 PubMedCrossRef

21.

Chen L, Yang S, Jakoncic J, Zhang JJ, Huang XY (2010) Migrastatin analogues target fascin to block tumour metastasis. Nature 464(7291):1062–1066. doi:10.1038/nature08978 PubMedCrossRef

22.

Pan X, Han H, Wang L, Yang L, Li R, Li Z, Liu J, Zhao Q, Qian M, Liu M, Du B (2011) Nitidine chloride inhibits breast cancer cells migration and invasion by suppressing c-Src/FAK associated signaling pathway. Cancer Lett 313(2):181–191. doi:10.1016/j.canlet.2011.09.001 PubMedCrossRef

23.

Sun CK, Man K, Ng KT, Ho JW, Lim ZX, Cheng Q, Lo CM, Poon RT, Fan ST (2008) Proline-rich tyrosine kinase 2 (Pyk2) promotes proliferation and invasiveness of hepatocellular carcinoma cells through c-Src/ERK activation. Carcinogenesis 29(11):2096–2105. doi:10.1093/carcin/bgn203 PubMedCrossRef

24.

Gaul C, Njardarson JT, Shan D, Dorn DC, Wu KD, Tong WP, Huang XY, Moore MA, Danishefsky SJ (2004) The migrastatin family: discovery of potent cell migration inhibitors by chemical synthesis. J Am Chem Soc 126(36):11326–11337. doi:10.1021/ja048779q PubMedCrossRef

25.

Yi ZF, Cho SG, Zhao H, Wu YY, Luo J, Li D, Yi T, Xu X, Wu Z, Liu M (2009) A novel peptide from human apolipoprotein(a) inhibits angiogenesis and tumor growth by targeting c-Src phosphorylation in VEGF-induced human umbilical endothelial cells. Int J Cancer 124(4):843–852. doi:10.1002/ijc.24027 PubMedCrossRef

26.

Hsia DA, Mitra SK, Hauck CR, Streblow DN, Nelson JA, Ilic D, Huang S, Li E, Nemerow GR, Leng J, Spencer KS, Cheresh DA, Schlaepfer DD (2003) Differential regulation of cell motility and invasion by FAK. J Cell Biol 160(5):753–767. doi:10.1083/jcb.200212114jcb.200212114 PubMedCrossRef

27.

To C, Shilton BH, Di Guglielmo GM (2010) Synthetic triterpenoids target the Arp2/3 complex and inhibit branched actin polymerization. J Biol Chem 285(36):27944–27957. doi:10.1074/jbc.M110.103036 PubMedCrossRef

28.

Serrels B, Serrels A, Brunton VG, Holt M, McLean GW, Gray CH, Jones GE, Frame MC (2007) Focal adhesion kinase controls actin assembly via a FERM-mediated interaction with the Arp2/3 complex. Nat Cell Biol 9(9):1046–1056. doi:10.1038/ncb1626 PubMedCrossRef

29.

Pang X, Yi T, Yi Z, Cho SG, Qu W, Pinkaew D, Fujise K, Liu M (2009) Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways. Cancer Res 69(2):518–525. doi:10.1158/0008-5472.CAN-08-2531 PubMedCrossRef

30.

Aslakson CJ, Miller FR (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52(6):1399–1405PubMed

31.

Pulaski BA, Ostrand-Rosenberg S (1998) Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 58(7):1486–1493PubMed

32.

Malkas LH, Herbert BS, Abdel-Aziz W, Dobrolecki LE, Liu Y, Agarwal B, Hoelz D, Badve S, Schnaper L, Arnold RJ, Mechref Y, Novotny MV, Loehrer P, Goulet RJ, Hickey RJ (2006) A cancer-associated PCNA expressed in breast cancer has implications as a potential biomarker. Proc Natl Acad Sci USA 103(51):19472–19477. doi:10.1073/pnas.0604614103 PubMedCrossRef

33.

Blanc C, Deveraux QL, Krajewski S, Janicke RU, Porter AG, Reed JC, Jaggi R, Marti A (2000) Caspase-3 is essential for procaspase-9 processing and cisplatin-induced apoptosis of MCF-7 breast cancer cells. Cancer Res 60(16):4386–4390PubMed

34.

Diez S, Gerisch G, Anderson K, Muller-Taubenberger A, Bretschneider T (2005) Subsecond reorganization of the actin network in cell motility and chemotaxis. Proc Natl Acad Sci USA 102(21):7601–7606. doi:10.1073/pnas.0408546102 PubMedCrossRef

35.

Otto AM, Muller CS, Huff T, Hannappel E (2002) Chemotherapeutic drugs change actin skeleton organization and the expression of beta-thymosins in human breast cancer cells. J Cancer Res Clin Oncol 128(5):247–256. doi:10.1007/s00432-002-0332-7 PubMedCrossRef

36.

Machesky LM, Insall RH (1998) Scar1 and the related Wiskott-Aldrich syndrome protein, WASP, regulate the actin cytoskeleton through the Arp2/3 complex. Curr Biol 8(25):1347–1356PubMedCrossRef

37.

Robinson RC, Turbedsky K, Kaiser DA, Marchand JB, Higgs HN, Choe S, Pollard TD (2001) Crystal structure of Arp2/3 complex. Science 294(5547):1679–1684. doi:10.1126/science.1066333294/5547/1679 PubMedCrossRef

38.

Kelleher JF, Atkinson SJ, Pollard TD (1995) Sequences, structural models, and cellular localization of the actin-related proteins Arp2 and Arp3 from Acanthamoeba. J Cell Biol 131(2):385–397PubMedCrossRef

39.

Wu X, Gan B, Yoo Y, Guan JL (2005) FAK-mediated src phosphorylation of endophilin A2 inhibits endocytosis of MT1-MMP and promotes ECM degradation. Dev Cell 9(2):185–196. doi:10.1016/j.devcel.2005.06.006 PubMedCrossRef

40.

Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92(8):827–839. doi:10.1161/01.RES.0000070112.80711.3D92/8/827 PubMedCrossRef

41.

Ogier C, Bernard A, Chollet AM, Le Diguardher T, Hanessian S, Charton G, Khrestchatisky M, Rivera S (2006) Matrix metalloproteinase-2 (MMP-2) regulates astrocyte motility in connection with the actin cytoskeleton and integrins. Glia 54(4):272–284. doi:10.1002/glia.20349 PubMedCrossRef

42.

Sadzuka Y, Hatakeyama H, Daimon T, Sonobe T (2008) Screening of biochemical modulator by tumor cell permeability of doxorubicin. Int J Pharm 354(1–2):63–69. doi:10.1016/j.ijpharm.2007.10.015 PubMedCrossRef

43.

Friedl P, Wolf K (2003) Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 3(5):362–374. doi:10.1038/nrc1075nrc1075 PubMedCrossRef

44.

Sun C, Zhang M, Shan X, Zhou X, Yang J, Wang Y, Li-Ling J, Deng Y (2010) Inhibitory effect of cucurbitacin E on pancreatic cancer cells growth via STAT3 signaling. J Cancer Res Clin Oncol 136(4):603–610. doi:10.1007/s00432-009-0698-x PubMedCrossRef

45.

Burridge K, Wennerberg K (2004) Rho and Rac take center stage. Cell 116(2):167–179PubMedCrossRef

46.

Sein TT, Thant AA, Hiraiwa Y, Amin AR, Sohara Y, Liu Y, Matsuda S, Yamamoto T, Hamaguchi M (2000) A role for FAK in the Concanavalin A-dependent secretion of matrix metalloproteinase-2 and -9. Oncogene 19(48):5539–5542. doi:10.1038/sj.onc.1203932 PubMedCrossRef

47.

Chen JS, Huang XH, Wang Q, Chen XL, Fu XH, Tan HX, Zhang LJ, Li W, Bi J (2010) FAK is involved in invasion and metastasis of hepatocellular carcinoma. Clin Exp Metastasis 27(2):71–82. doi:10.1007/s10585-010-9306-3 PubMedCrossRef

48.

Lu J, Guo H, Treekitkarnmongkol W, Li P, Zhang J, Shi B, Ling C, Zhou X, Chen T, Chiao PJ, Feng X, Seewaldt VL, Muller WJ, Sahin A, Hung MC, Yu D (2009) 14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell 16(3):195–207. doi:10.1016/j.ccr.2009.08.010 PubMedCrossRef

49.

Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S (1980) Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284(5751):67–68PubMedCrossRef

50.

Curran S, Murray GI (1999) Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 189(3):300–308. doi:10.1002/(SICI)1096-9896(199911)189:3<300:AID-PATH456>3.0.CO;2-C PubMedCrossRef

51.

Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Kalofonos H, Fountzilas G, Fotsis T, Pavlidis N (2005) Matrix metalloproteinases in carcinoma of unknown primary. Cancer 104(10):2282–2287. doi:10.1002/cncr.21454 PubMedCrossRef

Title: Cucurbitacin E inhibits breast tumor metastasis by suppressing cell migration and invasion
Authors: Tao Zhang
Jingjie Li
Yanmin Dong
Dong Zhai
Li Lai
Fujun Dai
Huayun Deng
Yihua Chen
Mingyao Liu
Zhengfang Yi
Publication date: 01-09-2012
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-012-2175-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

MMP-9 increases HER2/neu expression and alters apoptosis levels in human mammary epithelial cells (HMEC)

Assessment accuracy of core needle biopsy for hormone receptors in breast cancer: a meta-analysis

Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer

Systemic therapy options in BRCA mutation-associated breast cancer

Peritumoral FOXP3+ regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3+ regulatory T cell is prognostic predictor of breast cancer patients

Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer